In addition, G-CSF administration did not impact GVHD incidences or the onset of other vascular endothelial post-transplant complications, suggesting that its administration is safe in the alloHSCT setting conducted with PTCY [31,32,33]. Here, CSF3 is linked to graft versus host disease.